Champions Oncology, Inc. (CSBR) Stock Score, Valuation & Financial Research
Champions Oncology, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for CSBR
Champions Oncology, Inc. currently has a Wall Street Score of 25/100. The stored market price is $4.95. Its financial score is 41/100. Its valuation score is 0/100. The latest WSS change is -3.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What Champions Oncology, Inc. does
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. T
CSBR financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $4.95
- Market capitalization:
- $68.8M
- Revenue:
- $60.7M
- Net income:
- $-1.1M
- Free cash flow:
- $-5.0M
- Cash:
- $4.4M
- Total debt:
- $11.0M
- EPS:
- -0.08
- Financial score:
- 41/100
- Valuation score:
- 0/100
- Revenue score:
- 18/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-5.0M, showing cash burn in the current stored period.
- The balance sheet shows $4.4M of cash versus $11.0M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -3.7 points: CSBR decreased 3.7 points because Management declined by 40 points, Buffett declined by 5.4 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 41/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CSBR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.